NCT07388004

Brief Summary

Major depressive disorder (MDD) is one of the most common psychiatric conditions and often remains difficult to treat effectively. Many patients continue to experience residual symptoms or relapse even after receiving established forms of psychotherapy. This study tests whether targeting specific psychological mechanisms can improve outcomes for people with depression. We compare two novel group therapies: (1) Expectation-Focused Psychotherapeutic Intervention (EFPI), which aims to modify rigid, negative expectations that maintain depressive symptoms, and (2) Reward Enhancement and Activation Therapy (REACT), which focuses on increasing sensitivity to positive experiences and strengthening reward-related learning. Both are delivered in a group format to foster peer support and shared learning. A total of 150 adults with a current MDD diagnosis will be randomly assigned to EFPI, REACT, or a waiting-list control. Participants in the intervention groups receive 10 group sessions over five weeks. Waiting-list participants complete baseline and 3-month follow-up assessments before being offered standard treatment options. Clinical outcomes are assessed at baseline, immediately after treatment, and at 3- and 6-month follow-ups (for the intervention groups). Primary outcomes are reductions in depressive symptoms measured by clinician ratings and self-report questionnaires. Secondary outcomes include changes in expectation processes and reward sensitivity. In addition, functional MRI (fMRI) tasks examine brain mechanisms related to expectation updating and reward processing pre- and post-intervention, to help identify neural changes that may underlie symptom improvement. By directly addressing dysfunctional expectations and reduced reward sensitivity, this study seeks to provide evidence for more targeted psychotherapeutic approaches. If successful, the results may support more personalized treatments and better long-term outcomes in MDD.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
26mo left

Started Oct 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Oct 2025Jun 2028

Study Start

First participant enrolled

October 13, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 8, 2025

Completed
2 months until next milestone

First Posted

Study publicly available on registry

February 4, 2026

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2027

Expected
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2028

Last Updated

February 10, 2026

Status Verified

February 1, 2026

Enrollment Period

2.2 years

First QC Date

December 8, 2025

Last Update Submit

February 5, 2026

Conditions

Keywords

Major Depressive DisorderPsychotherapyGroup TherapyExpectation ViolationReward SensitivityMechanism-Based InterventionRandomized Clinical Trial

Outcome Measures

Primary Outcomes (1)

  • Change in Depressive Symptoms (Beck Depression Inventory-II)

    Change in depressive symptom severity assessed with the Beck Depression Inventory-II (BDI-II), a 21-item self-report questionnaire measuring cognitive, affective, and somatic symptoms of depression. Total scores range from 0 to 63, with higher scores indicating more severe depressive symptoms. The primary endpoint is the change from baseline to post-treatment (5 weeks). Symptom stability and maintenance will be examined at follow-up assessments.

    Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups

Secondary Outcomes (9)

  • Change in Depressive Symptoms (Hamilton Depression Rating Scale, 21-item)

    Baseline and post-treatment (5 weeks)

  • Depressive Expectations (Depressive Expectations Scale)

    Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups

  • Hopelessness (Beck Hopelessness Scale)

    Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups

  • Socially Negative Expectations (Social Anxiety-Negative Beliefs Scale, SANB-5)

    Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups

  • Behavioral Activation and Reward Responsiveness (Behavioral Activation System Scale)

    Baseline, post-treatment (5 weeks), 3-month and 6-month follow-ups

  • +4 more secondary outcomes

Study Arms (3)

Expectation-Focused Psychotherapeutic Intervention (EFPI)

EXPERIMENTAL

Participants receive 10 group therapy sessions (2 sessions per week over 5 weeks) of EFPI, a mechanism-based psychotherapy targeting maladaptive expectations. The intervention combines psychoeducation, structured behavioral experiments, and cognitive restructuring to systematically challenge negative expectations. A central focus is reducing cognitive immunization-the tendency to dismiss or reframe positive disconfirming evidence-to foster more flexible and adaptive belief updating. Sessions are conducted in small groups (5-10 participants) to facilitate peer modeling, social reinforcement, and shared learning. The first session includes baseline clinical assessments, and the final session includes immediate post-treatment assessments. All participants are additionally followed up at 3 and 6 months after the intervention to evaluate the persistence of treatment effects.

Behavioral: Expectation-Focused Psychotherapeutic Intervention

Reward Enhancement and Activation Therapy (REACT)

EXPERIMENTAL

Participants receive 10 group therapy sessions (2 sessions per week over 5 weeks) of REACT, a mechanism-based psychotherapy designed to enhance reward sensitivity. Core intervention components include attentional retraining toward rewarding stimuli, savoring exercises to prolong positive affect, and structured reinforcement plans to strengthen motivation and engagement in rewarding activities. Group discussions normalize difficulties in experiencing pleasure and provide strategies for sustaining rewarding behavior long-term. Sessions are conducted in small groups (5-10 participants). The first session includes baseline assessments, and the final session includes immediate post-treatment assessments. Long-term outcomes are assessed through follow-up evaluations at 3- and 6-months post-intervention.

Behavioral: Reward Enhancement and Activation Therapy

Waiting-List Control

NO INTERVENTION

Participants assigned to the waiting-list control condition do not receive active treatment during the initial 3-month period. They complete baseline assessments at study entry and a follow-up assessment after 3 months, corresponding to the time frame of the active intervention arms. After the 3-month assessment, participants are ethically permitted to pursue standard care outside the study. For comparability and long-term analyses, waiting-list participants continue to complete follow-up assessments at 6 months, including questions about any additional treatments received after the waiting-list phase.

Interventions

EFPI is a manualized group psychotherapy for major depressive disorder that directly targets maladaptive expectations. The treatment integrates psychoeducation, cognitive restructuring, and behavioral experiments to modify negative expectancies and reduce cognitive immunization, thereby enhancing adaptive expectation updating. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).

Also known as: EFPI
Expectation-Focused Psychotherapeutic Intervention (EFPI)

REACT is a manualized group psychotherapy for major depressive disorder that focuses on enhancing reward sensitivity and motivation. The intervention combines attentional retraining, savoring techniques, and reinforcement-based strategies to increase engagement with rewarding stimuli and experiences. Delivery: Group format (5-10 participants), 10 sessions (twice weekly for 5 weeks).

Also known as: REACT
Reward Enhancement and Activation Therapy (REACT)

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 18-80 years
  • Current diagnosis of major depressive disorder (MDD) according to DSM-5, confirmed by structured clinical interview (e.g., DIPS)
  • Hamilton Depression Rating Scale (HAMD-21) score ≥ 9
  • Ability to attend group therapy sessions (2×/week for 5 weeks)
  • Ability to undergo MRI scanning (for participants in the fMRI component) Written informed consent

You may not qualify if:

  • Current or lifetime diagnosis of bipolar disorder, psychotic disorder, or primary substance use disorder
  • High acute suicide risk requiring immediate intervention
  • Severe neurological disorder, brain injury, or contraindications for MRI (e.g., metal implants, claustrophobia)
  • Ongoing psychotherapy or initiation of a new antidepressant medication within the past 4 weeks
  • Insufficient German language proficiency to participate in therapy and complete study assessments
  • Cognitive impairment or other conditions interfering with informed consent or study participation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Philipps-University Marburg

Marburg, Hesse, 35032, Germany

RECRUITING

Related Publications (26)

  • Treadway MT, Zald DH. Reconsidering anhedonia in depression: lessons from translational neuroscience. Neurosci Biobehav Rev. 2011 Jan;35(3):537-55. doi: 10.1016/j.neubiorev.2010.06.006. Epub 2010 Jul 11.

    PMID: 20603146BACKGROUND
  • Whitton AE, Treadway MT, Pizzagalli DA. Reward processing dysfunction in major depression, bipolar disorder and schizophrenia. Curr Opin Psychiatry. 2015 Jan;28(1):7-12. doi: 10.1097/YCO.0000000000000122.

    PMID: 25415499BACKGROUND
  • Watkins E, Brown RG. Rumination and executive function in depression: an experimental study. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):400-2. doi: 10.1136/jnnp.72.3.400.

    PMID: 11861707BACKGROUND
  • Kazdin AE. Mediators and mechanisms of change in psychotherapy research. Annu Rev Clin Psychol. 2007;3:1-27. doi: 10.1146/annurev.clinpsy.3.022806.091432.

    PMID: 17716046BACKGROUND
  • Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov;163(11):1905-17. doi: 10.1176/ajp.2006.163.11.1905.

    PMID: 17074942BACKGROUND
  • Rief W, Shedden-Mora MC, Laferton JA, Auer C, Petrie KJ, Salzmann S, Schedlowski M, Moosdorf R. Preoperative optimization of patient expectations improves long-term outcome in heart surgery patients: results of the randomized controlled PSY-HEART trial. BMC Med. 2017 Jan 10;15(1):4. doi: 10.1186/s12916-016-0767-3.

    PMID: 28069021BACKGROUND
  • Rief W, Anna Glombiewski J. The role of expectations in mental disorders and their treatment. World Psychiatry. 2017 Jun;16(2):210-211. doi: 10.1002/wps.20427. No abstract available.

    PMID: 28498580BACKGROUND
  • Potsch L, Rief W. Transdiagnostic considerations of the relationship between reward sensitivity and psychopathological symptoms - a cross-lagged panel analysis. BMC Psychiatry. 2023 Sep 4;23(1):650. doi: 10.1186/s12888-023-05139-3.

    PMID: 37667190BACKGROUND
  • Pizzagalli DA. Toward a Better Understanding of the Mechanisms and Pathophysiology of Anhedonia: Are We Ready for Translation? Am J Psychiatry. 2022 Jul;179(7):458-469. doi: 10.1176/appi.ajp.20220423.

    PMID: 35775159BACKGROUND
  • Pizzagalli DA. Depression, stress, and anhedonia: toward a synthesis and integrated model. Annu Rev Clin Psychol. 2014;10:393-423. doi: 10.1146/annurev-clinpsy-050212-185606.

    PMID: 24471371BACKGROUND
  • Pan PM, Sato JR, Paillere Martinot ML, Martinot JL, Artiges E, Penttila J, Grimmer Y, van Noort BM, Becker A, Banaschewski T, Bokde ALW, Desrivieres S, Flor H, Garavan H, Ittermann B, Nees F, Papadopoulos Orfanos D, Poustka L, Frohner JH, Whelan R, Schumann G, Westwater ML, Grillon C, Cogo-Moreira H, Stringaris A, Ernst M; IMAGEN Consortium. Longitudinal Trajectory of the Link Between Ventral Striatum and Depression in Adolescence. Am J Psychiatry. 2022 Jul;179(7):470-481. doi: 10.1176/appi.ajp.20081180. Epub 2022 May 18.

    PMID: 35582783BACKGROUND
  • Kube T, Schwarting R, Rozenkrantz L, Glombiewski JA, Rief W. Distorted Cognitive Processes in Major Depression: A Predictive Processing Perspective. Biol Psychiatry. 2020 Mar 1;87(5):388-398. doi: 10.1016/j.biopsych.2019.07.017. Epub 2019 Jul 29.

    PMID: 31515055BACKGROUND
  • Kube T, Rief W, Gollwitzer M, Gartner T, Glombiewski JA. Why dysfunctional expectations in depression persist - Results from two experimental studies investigating cognitive immunization. Psychol Med. 2019 Jul;49(9):1532-1544. doi: 10.1017/S0033291718002106. Epub 2018 Aug 22.

    PMID: 30131084BACKGROUND
  • Kirchner L, Rief W, Muller L, Buchwald H, Fuhrmann K, Berg M. Depressive symptoms and the processing of unexpected social feedback: Differences in surprise levels, feedback acceptance, and "immunizing" cognition. PLoS One. 2024 Aug 26;19(8):e0307035. doi: 10.1371/journal.pone.0307035. eCollection 2024.

    PMID: 39186743BACKGROUND
  • Insel TR, Cuthbert BN. Medicine. Brain disorders? Precisely. Science. 2015 May 1;348(6234):499-500. doi: 10.1126/science.aab2358. No abstract available.

    PMID: 25931539BACKGROUND
  • Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A. The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses. Cognit Ther Res. 2012 Oct 1;36(5):427-440. doi: 10.1007/s10608-012-9476-1. Epub 2012 Jul 31.

    PMID: 23459093BACKGROUND
  • Greenberg T, Chase HW, Almeida JR, Stiffler R, Zevallos CR, Aslam HA, Deckersbach T, Weyandt S, Cooper C, Toups M, Carmody T, Kurian B, Peltier S, Adams P, McInnis MG, Oquendo MA, McGrath PJ, Fava M, Weissman M, Parsey R, Trivedi MH, Phillips ML. Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. Am J Psychiatry. 2015 Sep 1;172(9):881-91. doi: 10.1176/appi.ajp.2015.14050594. Epub 2015 Jul 17.

    PMID: 26183698BACKGROUND
  • Friston K. The free-energy principle: a unified brain theory? Nat Rev Neurosci. 2010 Feb;11(2):127-38. doi: 10.1038/nrn2787. Epub 2010 Jan 13.

    PMID: 20068583BACKGROUND
  • Fried EI, Nesse RM. Depression sum-scores don't add up: why analyzing specific depression symptoms is essential. BMC Med. 2015 Apr 6;13:72. doi: 10.1186/s12916-015-0325-4.

    PMID: 25879936BACKGROUND
  • Ferrari A, Richter D, de Lange FP. Updating Contextual Sensory Expectations for Adaptive Behavior. J Neurosci. 2022 Nov 23;42(47):8855-8869. doi: 10.1523/JNEUROSCI.1107-22.2022. Epub 2022 Oct 24.

    PMID: 36280262BACKGROUND
  • Fazeli S, Buchel C. Pain-Related Expectation and Prediction Error Signals in the Anterior Insula Are Not Related to Aversiveness. J Neurosci. 2018 Jul 18;38(29):6461-6474. doi: 10.1523/JNEUROSCI.0671-18.2018. Epub 2018 Jun 22.

    PMID: 29934355BACKGROUND
  • Ewen AI, Bleichhardt G, Rief W, Von Blanckenburg P, Wambach K, Wilhelm M. Expectation focused and frequency enhanced cognitive behavioural therapy for patients with major depression (EFFECT): a study protocol of a randomised active-control trial. BMJ Open. 2023 Mar 22;13(3):e065946. doi: 10.1136/bmjopen-2022-065946.

    PMID: 36948546BACKGROUND
  • D'Astolfo L, Rief W. Learning about Expectation Violation from Prediction Error Paradigms - A Meta-Analysis on Brain Processes Following a Prediction Error. Front Psychol. 2017 Jul 28;8:1253. doi: 10.3389/fpsyg.2017.01253. eCollection 2017.

    PMID: 28804467BACKGROUND
  • Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Ebert D, Karyotaki E. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023 Feb;22(1):105-115. doi: 10.1002/wps.21069.

    PMID: 36640411BACKGROUND
  • Cuijpers P, Karyotaki E, Weitz E, Andersson G, Hollon SD, van Straten A. The effects of psychotherapies for major depression in adults on remission, recovery and improvement: a meta-analysis. J Affect Disord. 2014 Apr;159:118-26. doi: 10.1016/j.jad.2014.02.026. Epub 2014 Feb 24.

    PMID: 24679399BACKGROUND
  • Beck AT, Haigh EA. Advances in cognitive theory and therapy: the generic cognitive model. Annu Rev Clin Psychol. 2014;10:1-24. doi: 10.1146/annurev-clinpsy-032813-153734. Epub 2014 Jan 2.

    PMID: 24387236BACKGROUND

Related Links

MeSH Terms

Conditions

Depressive Disorder, Major

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Study Officials

  • Winfried Rief, Prof. Dr.

    Philipps University Marburg

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Masia Fernanda Hoffmann, M.Sc.

CONTACT

Winfried Rief, Prof. Dr.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Independent outcome assessors conducting clinician-rated measures (e.g., HAMD-21) will remain blinded to group allocation. Participants, therapists, and investigators are not blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomly assigned in equal proportions to one of three parallel groups: EFPI, REACT, or waiting-list control.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 8, 2025

First Posted

February 4, 2026

Study Start

October 13, 2025

Primary Completion (Estimated)

December 31, 2027

Study Completion (Estimated)

June 30, 2028

Last Updated

February 10, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

De-identified individual participant data (IPD) will be made available upon reasonable request after publication of the main results, in accordance with DFG and CRC/TRR 393 data sharing policies. Data access will require a data use agreement and ethical approval.

Shared Documents
STUDY PROTOCOL, SAP, ICF, ANALYTIC CODE
Time Frame
Data and supporting documents will be available within 12 months after publication of the primary outcomes and will remain accessible for at least 10 years thereafter.
Access Criteria
De-identified individual participant data (IPD), study protocol, statistical analysis plan, and informed consent form will be made available to qualified researchers upon reasonable request. Access will be provided via the Open Science Framework (OSF) project page once data are curated and anonymized. Requests for access can be directed to the principal investigators of Project C02 within the CRC/TRR 393. Data will be available for scientific use after publication of the main results.

Locations